Sema4

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights.

[Sema4 @sema4]

Happy New Year to everyone, including all our valued customers, patients, partners, and employees. We wish you a healthy and safe 2023.

[GeneDx @GeneDx]

Last week we exhibited at #HotTopicsNeo2022, showcasing our research and collaboration efforts, the benefits of #exome sequencing over panel testing, & the clinical utility of #genome sequencing in the #NICU. Learn more about our offerings: https://t.co/73XjqxyLIT

[Sema4 @sema4]

A recent study we worked on with @UW and @seattlechildren's Hospital shows the clear benefits of rapid whole #genome sequencing for diagnosing critically ill #newborns in the #NICU. Learn more about the results of the research: https://t.co/PL7QYrPZZI.

[GeneDx @GeneDx]

#Exome sequencing is now recognized as a first-tier #genetic testing option for unexplained #epilepsy by the @GeneticCouns and the @AmEpilepsySoc. At #AES2022, we spoke with providers about the benefits of genetic testing for their #patients. Learn more: https://t.co/muR1EWBDDa.

[Sema4 @sema4]

We have announced new research highlighting the importance of rapid #exome sequencing for #mitochondrial diseases in the #NICU. Our study underscores the opportunity to improve health outcomes for infants with early medical intervention. Learn more: https://t.co/AvsBg9jLL0.

[GeneDx @GeneDx]

Attending #HotTopicsNeo2022? Join our sponsored lunch symposium to learn about rapid #genome sequencing and discuss clinical applications in the #NICU setting. Register here: https://t.co/6k3zNBx6a1.

[GeneDx @GeneDx]

We stand with @AmEpilepsySoc in supporting @GeneticCouns’ new guidelines recommending #exome sequencing as a first-tier test for individuals with unexplained #epilepsy. Visit us at #AES2022 to learn about #genetic testing for #patients with epilepsy. https://t.co/FUS5C5KQ3k.

[GeneDx @GeneDx]

Attending #HotTopicsNeo2022? Stop by booth #240 to learn about our #genetic testing offerings. Also explore how we support providers with actionable insights to inform medical management through our whole #genome & whole #exome sequencing: https://t.co/hOszMtRHWb.

[GeneDx @GeneDx]

We’re excited to exhibit at #AES2022 in Nashville, TN from 12/2 - 12/6. Join us on Friday, 12/2 from 9am-12pm CT at the ”Genetic Testing in Epilepsy: Improving Outcomes and Informing Gaps in Research” Symposium and stop by booth 1103 to learn about our #genetic testing offerings.

[Sema4 @sema4]

What are the goals of the GUARDIAN study? Learn how we’ll impact the lives of 100k #newborns in #NewYork and why we were selected to provide whole #genome sequencing & interpretation services for the landmark study: https://t.co/8U90jtEyJ6.

[Sema4 @sema4]

On this #Thanksgiving, we’d like to sincerely thank our patients, customers, and partners for their support and for being at the core of our mission to deliver personalized, actionable #health insights. We hope you have a joyous holiday. Happy Thanksgiving!

[GeneDx @GeneDx]

Supporting organizations like @DDX3X is an important part of our work, and we were proud to attend their annual scientific conference with members of our #genetic counseling team. Learn more about how GeneDx supports #patients & families through advocacy: https://t.co/jGebAzdoni.

[Sema4 @sema4]

.@LabPulse1 featured our recent collaboration with @MassGeneralNews on new research demonstrating #genome & #exome sequencing deliver more diagnostic certainty than multi-gene panels. Read more: https://t.co/nwAXEVCFd5.

[Sema4 @sema4]

Sema4 today announced 3Q 2022 business highlights and financial results, and a new strategic direction that the company believes will enable it to scale to profitability. Read more: https://t.co/tWu4hgfCv1. $SMFR

[Sema4 @sema4]

Happy #GeneticCounselorAwareness Day! We celebrate all #GeneticCounselors, their valuable skills & the critical role they play in #patients’ lives. Learn how our GCs help patients & clinicians understand the complexity of #genetic information: https://t.co/XUIB4dj3DR. #GCchat

[Sema4 @sema4]

What is the driving force behind the groundbreaking GUARDIAN study? Read our recent Q&A with Chief Medical Officer of GeneDx at Sema4, @paul_kruszka, to learn how our whole #genome sequencing will impact the lives of 100k+ #newborns in #NewYorkCity: https://t.co/4Dqye4Dcpj.

[Sema4 @sema4]

We’re presenting new research at #NSGC22 next week. Meet us at booth #417 to learn about our research, offerings, & more. Also visit our website to explore how we support the #patient journey through our whole #genome sequencing & whole #exome sequencing: https://t.co/AhxSRuSScJ.

[Sema4 @sema4]

November is #NativeAmericanHeritageMonth. We recognize and honor the culture and contributions of Native Americans, Alaska Natives, Native Hawaiians, and all indigenous people this month and beyond. #NAHM

[Sema4 @sema4]

Sema4 will release financial results for the third quarter of 2022 before the market opens on Monday, November 14th. On the same day, we will host a conference call to discuss financial and operating results at 8:30 a.m. ET. Read more: https://t.co/C5YqyGkqg5.

[Sema4 @sema4]

.@lifesciencesint recently interviewed Dr. @paul_kruszka, CMO of GeneDx at Sema4, on our role in the GUARDIAN study, the benefits of implementing whole #genome sequencing as the standard of care, & the need for this scientific advancement in #healthcare: https://t.co/QgWK2B0eNL.